+

PE20091674A1 - Antagonistas del receptor de glucagon - Google Patents

Antagonistas del receptor de glucagon

Info

Publication number
PE20091674A1
PE20091674A1 PE2009000369A PE2009000369A PE20091674A1 PE 20091674 A1 PE20091674 A1 PE 20091674A1 PE 2009000369 A PE2009000369 A PE 2009000369A PE 2009000369 A PE2009000369 A PE 2009000369A PE 20091674 A1 PE20091674 A1 PE 20091674A1
Authority
PE
Peru
Prior art keywords
seq
receptor antagonists
glucagon receptor
fab
antibody
Prior art date
Application number
PE2009000369A
Other languages
English (en)
Inventor
Rohn Lee Millican Jr
Andrew Ihor Korytko
Brian John Ondek
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40794248&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20091674(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20091674A1 publication Critical patent/PE20091674A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

REFERIDA A UN ANTICUERPO MONOCLONAL HUMANIZADO QUE COMPRENDE EL FRAGMENTO Fab, CARACTERIZADO POR SER CAPAZ DE ENLAZAR A LOS RECEPTORES DE GLUCAGON HUMANO, RATA Y MURINO CON UN Ki DE MANOS DE 50nM. DICHO FRAGMENTO FaB COMPRENDE: A) UNA CADENA LIGERA CDRL1: SEQ ID N0:53; CDRL2: SEQ ID N0:54; CDRL3: SEQ ID N0: 55; B) UNA CADENA PESADA CDRH1: SEQ ID N0: 56; CDRH2: SEQ ID N0: 57; CDRH3: SEQ ID N0:58. REFERIDA TAMBIEN AL VECTOR Y A UNA COMPOSICION FARMACEUTICA. DICHO ANTICUERPO ES UTIL EN EL TRATAMIENTO DE DIABETES TIPO I O II Y TRASTORNOS RELACIONADOS
PE2009000369A 2008-03-27 2009-03-12 Antagonistas del receptor de glucagon PE20091674A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3990708P 2008-03-27 2008-03-27

Publications (1)

Publication Number Publication Date
PE20091674A1 true PE20091674A1 (es) 2009-11-04

Family

ID=40794248

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2009000369A PE20091674A1 (es) 2008-03-27 2009-03-12 Antagonistas del receptor de glucagon

Country Status (15)

Country Link
US (2) US7968686B2 (es)
EP (1) EP2268670A1 (es)
JP (1) JP5438095B2 (es)
KR (1) KR101235934B1 (es)
CN (1) CN101983208A (es)
AR (1) AR070844A1 (es)
AU (1) AU2009228866A1 (es)
BR (1) BRPI0910118A2 (es)
CA (1) CA2719761A1 (es)
CL (1) CL2009000586A1 (es)
EA (1) EA201071126A1 (es)
MX (1) MX2010010517A (es)
PE (1) PE20091674A1 (es)
TW (1) TW201000126A (es)
WO (1) WO2009120530A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009352373B2 (en) * 2009-09-08 2016-05-12 Neopharm Co., Ltd. Antibodies against glucagon receptor and their use
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
JO3756B1 (ar) 2010-11-23 2021-01-31 Regeneron Pharma اجسام مضادة بشرية لمستقبلات الجلوكاجون
US8771696B2 (en) 2010-11-23 2014-07-08 Regeneron Pharmaceuticals, Inc. Method of reducing the severity of stress hyperglycemia with human antibodies to the glucagon receptor
ES2865068T3 (es) 2011-01-14 2021-10-14 Univ California Anticuerpos terapéuticos contra la proteína ROR-1 y métodos para usarlos
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013059531A1 (en) * 2011-10-20 2013-04-25 Genentech, Inc. Anti-gcgr antibodies and uses thereof
EP2785740A1 (en) 2011-12-02 2014-10-08 Eli Lilly and Company Anti-glucagon antibodies and uses thereof
SG11201508264UA (en) 2013-05-07 2015-11-27 Rinat Neuroscience Corp Anti-glucagon receptor antibodies and methods of use thereof
BR112016028726A2 (pt) * 2014-06-08 2017-11-07 Remd Biotherapeutics Inc métodos de tratamento de um paciente diagnosticado com diabetes tipo 1, métodos de redução, supressão, atenuação ou inibição de um ou mais sintomas associados com t1d, e métodos de tratamento de um paciente que está em risco de t1d
AU2017321423C1 (en) 2016-08-30 2025-01-30 Regeneron Pharmaceuticals, Inc. Methods of treating severe insulin resistance by interfering with glucagon receptor signaling
US20190248888A1 (en) 2016-10-20 2019-08-15 Regeneron Pharmaceuticals, Inc. Methods of lowering blood glucose levels
CN110520151B (zh) * 2017-01-27 2024-04-12 恩格姆生物制药公司 胰高血糖素受体结合蛋白和其使用方法
MX2020002057A (es) 2017-08-22 2020-07-13 Regeneron Pharma Metodos para tratar trastornos del ciclo de la urea mediante interferencia con la señalizacion del receptor del glucagon.
CN110357959B (zh) * 2018-04-10 2023-02-28 鸿运华宁（杭州）生物医药有限公司 Gcgr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用
WO2020023847A1 (en) 2018-07-27 2020-01-30 Ngm Biopharmaceuticals, Inc. Use of glucagon receptor antagonists with immunotherapeutic agent
WO2020125744A1 (zh) 2018-12-21 2020-06-25 江苏恒瑞医药股份有限公司 双特异性蛋白

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776725A (en) 1992-08-28 1998-07-07 Zymogenetics, Inc. Recombinant production of glucagon receptors
ATE285472T1 (de) 1992-08-28 2005-01-15 Novo Nordisk As Glucagonrezeptoren
AU2002239538A1 (en) 2000-12-06 2002-06-18 Deltagen, Inc. Transgenic mice containing glucagon receptor gene disruptions
AR036711A1 (es) * 2001-10-05 2004-09-29 Bayer Corp Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
US7399853B2 (en) 2003-04-28 2008-07-15 Isis Pharmaceuticals Modulation of glucagon receptor expression
WO2006005469A2 (en) 2004-07-15 2006-01-19 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with glucagon receptor (gcgr)
JP5001364B2 (ja) 2006-07-04 2012-08-15 ブラッコ イメージング ソチエタ ペル アチオニ 腫瘍性組織等の生物組織を局部的に熱剥離するための装置
CL2007002668A1 (es) * 2006-09-20 2008-05-09 Amgen Inc Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2.

Also Published As

Publication number Publication date
TW201000126A (en) 2010-01-01
JP2011518125A (ja) 2011-06-23
KR101235934B1 (ko) 2013-02-21
KR20100117130A (ko) 2010-11-02
CL2009000586A1 (es) 2010-06-04
US20090252727A1 (en) 2009-10-08
CN101983208A (zh) 2011-03-02
BRPI0910118A2 (pt) 2015-12-29
US20110212092A1 (en) 2011-09-01
WO2009120530A1 (en) 2009-10-01
JP5438095B2 (ja) 2014-03-12
US7968686B2 (en) 2011-06-28
EP2268670A1 (en) 2011-01-05
AR070844A1 (es) 2010-05-05
EA201071126A1 (ru) 2011-04-29
MX2010010517A (es) 2010-12-20
CA2719761A1 (en) 2009-10-01
AU2009228866A1 (en) 2009-10-01

Similar Documents

Publication Publication Date Title
PE20091674A1 (es) Antagonistas del receptor de glucagon
AR080698A1 (es) Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
AR073770A1 (es) Anticuerpo aislado que se enlaza especificamente con, e induce la degradacion del receptor-3 del factor de crecimiento del fibroblasto humano (fgfr-3), fragmento de enlace fgfr-3 humano del mismo, composicion farmaceutica y producto que lo comprenden
MX395677B (es) Proteínas de unión para el receptor peptídico inhibidor gástrico (gipr) en combinación con agonistas de glp-1 para usarse en trastornos metabólicos
PE20120554A1 (es) Polipeptidos y metodo de tratamiento
CL2010001544A1 (es) Anticuerpo monoclonal humanizado o fragmento de union al mismo que se une y neutraliza al factor de crecimiento endotelial vascular humano (hvegf); composicion que lo comprende; acido nucleico codificante; vector; celula huesped; su uso para tratar o prevenir una enfermedad mediada por vegf; e hibridoma.
JP2020500538A5 (es)
ES2571129T3 (es) Anticuerpos anti-CTLA4 humanizados
PE20191148A1 (es) Tratamiento de la migrana refractaria
RS53750B1 (en) NOTCH1 RECEPTOR BINDING AGENTS AND APPLICATION PROCEDURES
PE20120899A1 (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b
PE20080262A1 (es) Anticuerpo humanizado contra interleuquina-18
HRP20171472T1 (hr) Optimizirana monoklonska protutijela protiv inhibitora puta tkivnog faktora (tfpi)
PE20090518A1 (es) Proteinas enlazantes de antigenos que enlazan al receptor de la interleucina 18 (il-18)
PE20080181A1 (es) Anticuerpos que se unen al peptido beta-amiloide en el tratamiento de alzheimer
RS52509B (en) ANTI-IL-17 ANTITELA
PE20121579A1 (es) Proteinas de enlace al antigeno il-23 humanas
PE20170687A1 (es) Proteinas de enlace a cd127
AR070346A1 (es) Anticuerpo especifico del receptor de linfopoyetina estromal timica (tslpr) y usos en trastornos inflamatorios e inflamatorios alergicos
CO6430469A2 (es) Anticuerpos humanizados que se unen a cd19 y sus usos
PE20091963A1 (es) Anticuerpos anti-flt3
PE20140133A1 (es) Nuevas proteinas de union a antigenos
PE20120343A1 (es) Anticuerpo anti-cmet que comprende una region bisagra
PE20061324A1 (es) Anticuerpos anti-il-6, composiciones, metodos y usos
PE20141660A1 (es) PROTEINAS DE UNION A ANTIGENO DE TNF-ALFA CON UNION A FcRn INCREMENTADA

Legal Events

Date Code Title Description
FD Application declared void or lapsed
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载